This video is the third in a five-part series that focuses on making sense of multiple myeloma treatment based upon the newly obtained input from the American Society of Hematology (ASH) in Orlando, FL.
- Smoldering Myeloma
- Frontline Therapy
- Significance of FiSH testing
- CAR T therapy/Bi-specific T Cell engagers/MoAb
- Novel agents/combinations
with an educational grant from:
Amgen Oncology, Takeda Oncology, Janssen Oncology